Acadia Pharmaceuticals | ACAD - Selling And Administration Expenses


Acadia Pharmaceuticals reported $124.9M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Eisai JPY 103.86B 3.7B Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
J&J USD 6.75B 831M Dec/2025
Moderna USD 268M 38M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Prothena USD 13.24M 2.67M Sep/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025